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Abstract
Nowadays, 2-ethylhexyl 4-(N,N-dimethylamino)benzoate (EDP) is one of the most widely
used UV ﬁlters in sunscreen cosmetics and other cosmetic products. However, undesirable
processes such as percutaneous absorption and biological activity have been attributed to
this compound. The in vitro metabolism of EDP was elucidated in the present work. First of all,
the phase I biotransformation was studied in rat liver microsomes and two metabolites,
N,N-dimethyl-p-aminobenzoic acid (DMP) and N-monomethyl-p-aminobenzoic acid
(MMP), were identiﬁed by GC-MS analysis. Secondly, the phase II metabolism was investi-
gated by means of LC-MS. The investigated reactions were acetylation and glucuronidation
working with rat liver cytosol and with both human and rat liver microsomes, respectively.
Analogue studies with p-aminobenzoic acid (PABA) were carried out in order to compare the
well established metabolic pathway of PABA with the unknown biotransformation of EDP. In
addition, a method for the determination of EDP and its two phase I metabolites in human
urine was developed. The methodology requires a solid-phase extraction prior to LC-MS
analysis. The method is based on standard addition quantiﬁcation and has been fully vali-
dated. The repeatability of the method, expressed as relative standard deviation, was in the
range 3.4–7.4% and the limit of detection for all quantiﬁed analytes was in the low ng mL
-1
range.
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Introduction
Both harmful and beneﬁcial health eﬀects
canberelatedtotheexposuretoultraviolet
(UV) solar radiation. While many of the
adverse eﬀects of excessive exposure are
wellknown,sunavoidancemayprovokea
sensitiveriskofautoimmunedisordersand
bone diseases, normally associated with
the maintenance of adequate levels of
vitamin D [1]. On the other hand, ery-
thema, edema and pigment darkening
followed by delayed tanning and photo-
aging, immunosuppression and photocar-
cinogenesis are the acute and chronic
response of human skin to excessive
ultraviolet irradiation, respectively [2].
The need for a balance in UV radia-
tion exposure that prevents the risk of
skin cancer and also maintains adequate
vitamin D levels is recommended. Some
strategies, such as wearing photoprotec-
tive clothing and considering recommen-
dations on ‘‘sun behavior’’, should be
taken into account for protection against
UV light [3]. In addition, among the dif-
ferent measures promoted to reduce the
deleterious eﬀects of UV radiation, the
use of topical sunscreen cosmetics con-
taining UV ﬁlters is regarded as ﬁrst-line
photoprotective modality [4, 5].
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siderably depending on the country.
Furthermore, the maximum allowed
concentrations of UV ﬁlters in the sun-
screens vary among national regulatory
agencies. Ethylhexyl dimethyl PABA
(EDP, 2-ethylhexyl 4-(N,N-dimethyl-
amino)benzoate), is an organic UV-ﬁlter
with molar absorbance in the UV-B
range (290–320 nm). According to the
European legislation and the US Food
and Drug Administration (FDA), EDP
can be used up to a maximum concen-
tration of 8% in cosmetic products,
whereas the Japanese legislation allows
its use up to 10% [5].
EDPiseﬃcientinprotectingfromUV
radiation-induced erythema and edema
[6] and also appears to oﬀer a valuable
level of protection against photocarcino-
genesis [7]. Moreover, an in vitro study
about the inﬂuence of UV ﬁlter concen-
trationonthesunprotectionfactor(SPF)
suggested that EDP is one of the most
eﬀective ﬁlters authorized [8] and addi-
tionally, is one of the most popular sun-
screen ingredients [9]. Despite the fact
that EDP shows almost ideal UV ﬁlter
characteristics and is claimed to be
chemically inert [10], evidences suggest
that its safety has to be studied more
carefully. In fact, some reports about the
systemic eﬀects of EDP, such as anti-
androgenic and estrogenic activities
[11–14], have been published. Moreover,
some observations suggest the potential
role of this xenoestrogen in combination
withsolarUVtoselectivelydamageDNA
[15, 16]. Additionally, it was shown that
the substance can be absorbed systemat-
ically through the skin surface [17–20].
Considering the above mentioned
eﬀects of EDP, this study was aimed to
supply information about the in vitro
metabolic pattern of EDP and to provide
an analytical tool in order to study the
absorption, accumulation and excretion
bioprocessesofthiswidelyusedUVﬁlter.
When xenobiotics enter the body,
generally the physical properties of these
chemicals change in a process called
biotransformation that does not always
lead to inactivation (detoxiﬁcation) of
the xenobiotic but, in some cases, may
lead to more active compounds (bioac-
tivation). The biotransformation of
xenobiotics is performed by a limited
number of enzymes with broad substrate
speciﬁcities. These catalytic enzymes are
generally divided in two classes, namely
phase I and phase II. Phase I enzymatic
reactions involve reduction, oxidation
and hydrolysis and facilitate a small in-
crease in hydrophilicity by introducing
hydroxyl, amino, carboxyl or thiol
groups into the molecule. On the other
hand, phase II enzymatic reactions result
in a large increase in hydrophilicity,
greatly promoting the excretion of the
compound from the body. Phase II
enzymatic reactions include acetylation,
sulfation, methylation, glucuronidation,
conjugation with amino acids and con-
jugation with glutathione [21].
The urinary route of excretion is the
primary elimination pathway of some
UV ﬁlters and their metabolites [22], a
number of reports about the determina-
tion of UV ﬁlters in human urine can be
found in literature [23–25]. With regard
to EDP, studies describing its determi-
nation in human plasma have also been
reported [26]. However, no reports con-
cerning the determination of EDP in
human urine or EDP and its metabolites
in any biological ﬂuid have been pub-
lished.
Due to the fact that the metabolism of
PABA (p-aminobenzoic acid) is well
known [27] and its structure is similar to
EDP, this substance was chosen as a
‘‘positive control’’ in the presented study.
Inaddition,itmustbeconsideredthatthe
high incidence of dermatological side
eﬀectsobservedforPABA[28–34]hasled
to the fact that this widely used sunscreen
ingredient is nowadays considered to be
adverse. Hence, the aim to study in depth
the systemic eﬀects that may be provoked
by the possible metabolites of EDP
should be encouraged.
The microsomal and cytosolic
metabolism of EDP was studied by
means of gas chromatography-mass
spectrometry (GC-MS) and liquid chro-
matography-mass spectrometry (LC-
MS) considering diﬀerent cofactors. This
report is also focus on the development
and validation of a sensitive method
based on solid-phase extraction (SPE)
prior to LC-MS analysis that allows the
determination of the parent compound
(EDP) and two of its identiﬁed metabo-
lites, DMP and MMP, in human urine.
In addition, the use of a phenyl column
allowed good retention and separation
of the highly hydrophilic analytes in the
LC-MS method.
Experimental
Reagents and Samples
2-Ethylhexyl 4-(N,N-dimethylamino)
benzoate 98% (EDP) (Aldrich, Milwau-
kee, USA), 4-(N,N-dimethylamino)
benzoic acid 98% (DMP), 4-acetamido-
benzoic acid (Aldrich, Barcelona, Spain),
4-(N-methylamino) benzoic acid 97%
(MMP) (Sigma-Aldrich, Schnelldorf,
Germany) and p-aminobenzoic acid
99.7% (PABA) (Guinama, Valencia,
Spain) were used as standards.
Trihexylamine (Eastman, Rochester,
USA) and caﬀeine (Janssen Chimica,
Geel, Belgium) were used as internal
standards (I.S.), for LC-MS and GC-MS
procedures, respectively. Methanol
(MeOH) absolute LC grade, acetonitrile
(ACN) LC gradient grade and formic
acid were from Biosolve B.V. (Leen-
derweg, The Netherlands), dichloro-
methane (DCM) 99.9% capillary GC
Grade was from Sigma-Aldrich (St.
Louis, USA), magnesium chloride
(MgCl2) hexahydrate   99% was from
Fluka Chemie (Steinheim, Germany),
potassium hydrogen phosphate and
2,2,2-triﬂuoro-N-methyl-N-(trimethylsilyl)
acetamide (MSTFA) were from Merck
(Darmstadt, Germany), acetic acid
99.8% and ammonia solution ca. 25%
were from Riedel-de Hae ¨ n (Seelze,
Germany). Deionized water was ob-
tained by using a Milli-Q device from
Millipore (Amsterdam, The Nether-
lands). b-Nicotinamide adenine dinucle-
otide 20-phosphate reduced tetrasodium
salt (NADPH), uridine 50-diphospho-
glucuronic acid trisodium salt (UDP-GA)
98–100%, adenosine 50-triphosphate
(ATP) magnesium salt (  95%) and
acetyl coenzyme A (AcCoA) sodium
salt   93% powder were purchased
from Sigma-Aldrich (Schnelldorf,
Germany). Paper ﬁlters 595 ½ 110 mm
were from Schleicher & Schuell (Dasel,
Germany), the SPE vacuum manifold
was from Waters (Milford, MA, USA).
SPE cartridges Bond Elut Plexa 30 mg
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Netherlands). Sodium chloride, potas-
sium chloride, calcium chloride, magne-
sium sulphate and hydrochloric acid
were from Sigma Aldrich (Schnelldorf,
Germany).
Urine samples were from human
volunteers who did not use any cosmetic
products containing EDP and were kept
at 4 C until analysis.
Gas Chromatography-Mass
Spectrometry
An HP 6890 gas chromatography sys-
tem, equipped with an HP 6890 injector
was used. The mass spectrometer (MS)
was an HP 5973 MSD (Agilent,
Waldbronn, Germany). The MS was
operated in full scan mode from 50–500
m/z. Electron impact ionization was
performed at 70 eV. The employed
column was a Factor Four 5MS 30 m 9
0.25 mm 9 0.25 lm (Varian, Darms-
tadt, Germany), operated under helium
(99.9990%) at a constant ﬂow rate of
1.0 mL min
-1. The oven program star-
ted at 50 C, held for 1 min, ramped
to 150 C with 30 C min
-1, ramped to
200 C with 5 C min
-1 and ﬁnally to
300 C with 10 C min
-1, held for
5 min. The transfer line temperature
was 270 C. The injector temperature
was 280 C. An Optic 2 ATAS pro-
grammable injector (ATAS, Cambridge,
England) was operated in splitless mode
(1 min) and the injection volume was
1 lL.
Liquid Chromatography-Mass
Spectrometry
The LC-MS system consisted of a
ShimadzuLC-2010A(Duisburg,Germany)
and an Agilent 1100 series Ion Trap
(Agilent, Waldbronn, Germany). The
MS was operated in positive electrospray
ionization (ESI+) mode, the capillary
voltage was set to 40 V, the nebulizer
pressure was 30 psi, the drying gas ﬂow
was 8 mL min
-1 (nitrogen 99.9990%)
and the temperature of the heated cap-
illary was 350 C. The MS operated in
scan mode from 50–500 m/z, in line with
a LC-2010A UV detector (Shimadzu,
Duisburg, Germany). The column used
was a XTerra Phenyl 2.1 9 100 mm,
3.5 lm (Waters, Milford, USA) coupled
to a C18 precolumn (4 mm 9 5 mm)
from Restek (Bad Homburg, Germany).
Phase A consisted of water:MeOH
(99.5:0.5, v/v) with 0.1% of formic acid,
phase B consisted of MeOH with 0.1%
of formic acid.
In the case of the determination of
EDP and its metabolites in urine, the
pumps supplied the following gradient at
22 C: 0–1 min, 0% phase B; 1–16 min
linear gradient to 100% phase B, held
for 8 min. The injection volume was
30 lL if not otherwise stated.
In the study of the in vitro phase II
metabolism of EDP, the pumps supplied
a gradient at 22 C of: 0–8 min, 0%
phase B; 8–16 min linear gradient to
100% phase B, held for 8 min. The
injection volume was 50 lL if not
otherwise stated. The MS–MS spectra
were produced by collision-induced dis-
sociation (CID) of the selected precursor
ions with helium (99.9990%) as the col-
lision gas.
In vitro Metabolism of EDP
The phase I metabolism of EDP was
examined by GC-MS and LC-MS,
whereas the phase II metabolism was
investigated by LC-MS only.
Rat liver microsomes and cytosol
were prepared following the procedure
described by Rooseboom et al. [35], and
stored at -80 C until use. Human liver
microsomes, pooled from 50 donors,
were obtained from Xenotech (Lot No.
0710619), containing 20 mg mL
-1 pro-
tein. Two 2 mM stock solutions of both
EDP (substrate solution) and PABA
were prepared separately in ACN and
stored at 4 C. A 100 mM potassium
phosphate solution containing 5 mM
MgCl2 at pH 7.4 (KPi solution) was also
prepared.
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Fig. 1. Proposed metabolism pathway of EDP
Table 1. GC-MS substance characteristics for EDP and its phase I metabolites
Substance Relative retention time m/z
b (%)
Caﬀeine (internal standard) 1.00 194 (100), 104 (90), 67 (80), 82 (60)
MMP-TMS
a 0.87 134 (100), 164 (50), 208 (40)
DMP-TMS
a 0.91 148 (100), 178 (50), 237 (40)
EDP 1.35 165 (100), 277 (40), 148 (30)
a Trimethylsilyl
b Mass to charge ratio
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of EDP, 50 lL of the rat liver microsomes
solution(ca.13 mg mL
-1)weremixedwith
the KPi solution and NADPH (20 mM in
KPi solution). Then, 5 lL of the substrate
solution were added, the ﬁnal volume was
500 lL. The mixture was maintained at
37 C for 1 h. Control incubations were
performed in the absence of substrate
solution or the rat liver microsomes solu-
tion. The reaction was terminated by the
addition of 10 lL formic acid. When the
reactionhadbeenstopped,themixturewas
vortexed and loaded onto the SPE
cartridges, prior to GC-MS analysis.
To investigate the phase II metabo-
lism of EDP, diﬀerent cofactors were
added to the incubation mixture. In
order to study the acetylation process,
50 lL of the rat liver cytosol solution
(ca. 38 mg mL
-1), KPi, NADPH, ATP
(10 mM in KPi) and AcCoA (10 mM in
KPi) were mixed. The glucuronidation
was assessed using both human and rat
liver microsomes, KPi, NADPH and
UDP-GA (10 mM in KPi). For both
conjugation processes, 5 lL of the sub-
strate solution were added to the corre-
sponding mixtures. In all cases, the ﬁnal
volume was 500 lL. The mixtures were
maintained at 37 C for 1 h. Control
incubations were performed in the
absence of substrate or protein solutions.
In addition to the aforementioned
experiments, analogue PABA incuba-
tions were carried out in the same man-
ner, in order to compare PABA and
EDP metabolism. The reaction was ter-
minated by the addition of 1,000 lL ice-
cold MeOH. When the reaction had
been stopped, the mixture was vortexed
and centrifuged at 5,0009g for 15 min at
room temperature. The supernatant was
evaporated to dryness under a gentle
stream of nitrogen at room temperature,
reconstituted in 150 lL of a mixture of
LC phases A and B (1:1, v/v) and ana-
lyzed by LC-MS.
Solid-Phase Extraction
Both the microsome incubation and the
urine samples were acidiﬁed with formic
acid (resulting pH 3) before loading to
the SPE cartridges. The cartridges were
conditioned with 2 mL of MeOH and
2 mL of water.
For GC-MS analysis, cartridges
were then loaded with the incubated
samples at a ﬂow rate of about
0.5 mL min
-1, washed with 0.5 mL of
water and dried under full vacuum for
10 min. The analytes were eluted with
2 9 0.5 mL of DCM:MeOH (1:1, v/v).
The eluate was evaporated to dryness
under a gentle stream of nitrogen at
room temperature and redisolved in
150 lL of ACN. 100 lL of the aceto-
nitrile solution were mixed with 20 lL
of both MSTFA and caﬀeine solution
(20 lgm L
-1 in ACN, internal stan-
dard) in a microvial insert. Finally, the
solution was injected into the GC-MS
system.
For LC-MS analysis, cartridges were
loaded with 5 mL of urine sample at a
ﬂow rate of about 0.5 mL min
-1,
washed with 5 mL of water and dried
under full vacuum for 10 min. The ana-
lytes were eluted with 3 9 0.4 mL of
DCM:MeOH (1:1, v/v). The eluate was
evaporated to dryness under a gentle
stream of nitrogen and the dried samples
were redisolved in 400 lL of a mixture
of phases A and B (1:1, v/v) and injected
into the LC-MS system.
Fig. 2. GC-MS chromatograms of (a) control incubation, in the absence of substrate solution,
and (b) sample incubation, containing the substrate solution
Table 2. Comparison of aqueous and real urine calibrations for MMP, DMP and EDP
Analyte Parameter Calibration (n = 5)
Artiﬁcial urine Real urine
MMP Slope (mL lg
-1) 0.106 ± 0.003 0.0175 ± 0.0004
Intercept (-3 ± 6) 9 10
-4 (1 ± 7) 9 10
-5
R
2 0.997 0.998
DMP Slope (mL lg
-1) 0.155 ± 0.003 0.0403 ± 0.0009
Intercept (-1 ± 6) 9 10
-5 (2 ± 1) 9 10
-4
R
2 0.998 0.998
EDP Slope (mL lg
-1) 2.02 ± 0.06 2.00 ± 0.02
Intercept (-1 ± 1) 9 10
-2 (-9 ± 4) 9 10
-3
R
2 0.996 0.999
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for the Determination
of EDP and Its Phase I
Metabolites in Human
Urine
A2 5lgm L
-1 trihexylamine solution in
MeOH (internal standard) and a multi-
component solution of EDP, DMP and
MMP at 25 lgm L
-1 in MeOH were
prepared.Urinesampleswereﬁrstﬁltered
through a paper ﬁlter. To prepare a
standard addition calibration, ﬁve ali-
quots of 9,640 lL of each urine sample
werespikedwith0,20,40,60and80 lLof
the multicomponent solution, to which
100, 80, 60, 40 and 20 lL of MeOH were
added, respectively, in order to reach the
same content of MeOH in the calibration
solutions. Thereafter, 200 lL of the
internal standard solution were added to
every solution. Finally, the urine solu-
tions were adjusted to pH 3 by adding
60 lL of formic acid. The ﬁnal volume of
the solutions was 10 mL. Each solution
was subjected to the SPE procedure de-
scribed above and the redisolved samples
wereinjectedintotheLC-MSsystemwith
the aforementioned conditions. Results
were obtained by using internal standard
calibration curves (analyte area/internal
standard area vs. concentration).
Results and Discussion
The analytical challenge was to deter-
mine the relatively non-polar base EDP
simultaneously with the two polar
amphoteric metabolites MMP and
DMP. The in vitro phase I metabolism
of EDP was ﬁrst studied by means of
microsomal incubations. Thereafter, an
SPE LC-MS method was developed and
validated for the determination of the
parent compound EDP and its metabo-
lites, DMP and MMP, in human urine.
Finally, the phase II metabolism of EDP
was studied and a comparison between
EDP and PABA was drawn.
Study of the Experimental
Variables
The employed Bond Elut Plexa car-
tridges showed a good capacity to retain
adequately both types of analytes, the
more lipophilic EDP as well as MMP
and DMP. The SPE procedure was
optimized for the clean-up of micro-
somal incubations with subsequent GC-
MS analysis and the extraction and
preconcentration processes of the iden-
tiﬁed phase I metabolites from urine.
Identiﬁcation of Phase I
Metabolites by Means
of GC-MS Analysis
During the microsomal study, MMP and
DMP (Fig. 1) were identiﬁed by GC-MS
analysis. Both substances were identiﬁed
by comparing the relative retention time
and the mass spectral data of the sily-
lated substances with reference material
(Table 1).
Figure 2 shows the chromatograms
obtained from the analysis of both con-
trol and sample incubations. As can be
seen, the addition of the substrate solu-
tion to the incubation mixture leads to
the formation of DMP and MMP. Both
metabolites were formed after the
cleavage of the 2-ethylhexyl group from
EDP, which allowed for the mono-syli-
lation of the acid moiety. The GC-MS
spectral data were in good agreement
with the proposed silylation site. In
order to determine if MMP arises from
EDP or DMP, an additional control
incubation was carried out using DMP
as the substrate. MMP was identiﬁed but
the intensity of the signal was signiﬁ-
cantly lower than in the case of EDP
incubation. This indicates that MMP
can be formed by the demethylation of
EDP and/or DMP. Control experiments
in the absence of microsomes did not
contain any detectable EDP metabolites,
therefore excluding sample degradation
as a source of the metabolites. The
extraction yield in comparison to an
external standard (4 lgm L
-1) during
the SPE-GC-MS study for EDP and
DMP were determined to be around 80
Fig. 3. Extracted ion chromatogram of a fortiﬁed urine sample at 250 ng mL
-1 subjected to the
described SPE-LC-MS method for (a) MMP (m/z = 152), DMP (m/z = 166) and (b) EDP
(m/z = 278), I.S. (internal standard, 500 ng mL
-1, m/z = 270)
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EDP were metabolized in the phase I
experiments. From this percentage of
metabolism, about 45 and 15% corre-
sponded to the formation of DMP and
MMP, respectively (Fig. 2).
Validation of SPE-LC-MS to
Determine EDP, DMP and MMP
in Human Urine
Two multicomponent calibrations pre-
pared in artiﬁcial urine [36] (artiﬁcial
urine calibration) and in analyte-free
urine (real urine calibration) were car-
ried out. Both calibrations were obtained
by measuring ﬁve solutions containing
between 50 and 250 ng mL
-1 of each
analyte. All solutions were fortiﬁed with
the internal standard solution (trihexyl-
amine) at 500 ng mL
-1 and the pH was
set to 3 by adding 60 lL of formic acid.
The fact that the calibrate intercepts
were statistically comparable to zero
proves for the selectivity of the method.
On the other hand, statistically diﬀerent
slopes were obtained when both aqueous
and real urine calibrations were com-
pared for MMP and DMP (Table 2). In
the case of EDP, no signiﬁcant diﬀerence
was obtained. Hence, in order to correct
the matrix interferences that aﬀect DMP
and MMP, the standard addition meth-
od was used for quantiﬁcation.
Figure 3 shows an extracted ion
chromatogram of a fortiﬁed analyte-free
urine sample containing 250 ng mL
-1 of
EDP, DMP and MMP.
Robustness—pH and Loading Capacity
Four portions taken from urine (analyte-
free) were spiked with 200 ng mL
-1 of
MMP, DMP and EDP. The pH was
adjusted to 3, 4, 6 and 9 by adding formic
acid, acetic acid, water and ammonia
solutions, respectively. Urine samples
were analyzed by the described method
and the results are shown in Fig. 4. The
response of EDP showed no pH depen-
dency, whereas MMP and DMP showed
decreasing responses at higher pH values.
This ﬁnding stands in good accordance
with the pKa values of the analytes (EDP
pKa about 2.5, MMP and DMP pKa1 and
pKa2 around 2.5 and 5, respectively [37]).
The obtained results were in good agree-
ment with the pH conditions obtained
during the optimization of the SPE pro-
cedure. The evaluation of the method
robustness also indicated that the extrac-
tion suitability of the three analytes was
optimal at pH values lower than 4.
The next experiment concerning the
robustness involved the study of the
loading capacity. Eluates from the car-
tridge were analyzed while increasing
volumes of sample were loaded. Car-
tridges were capable to load at least 5 mL
ofsample(150 ng mL
-1,750 ng)without
showing analyte breakthrough. Further-
more, the eﬃcacy of the elution solvent
was tested and it was found that 1 mL of
MeOH:DCM (1:1, v/v) was suitable to
elute the analytes quantitatively.
Accuracy Determination
The accuracy was evaluated through the
application of the developed method to
the analysis of urine samples taken from
diﬀerent human volunteers who were
known not to use any cosmetic products
containing EDP. Urine samples were
spiked with known amounts of MMP,
DMP and EDP. Table 3 shows the
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Fig. 4. Eﬀect of the pH on the extraction of MMP (a), DMP (b) and EDP (c) from human urine
(200 ng mL
-1 level). Error bars show standard deviation (n = 3)
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The standard deviation (sXE) was ob-
tained as the standard deviation of the
extrapolated value in the standard
addition line [38].
The Student’s t test was used to proof
that both found and added concentra-
tion values were statistically comparable.
The t test did not show any signiﬁcant
diﬀerences between the found values and
the real values.
Validation Parameters
The calibration graphs (n = 5) were
linear for EDP, DMP and MMP over a
concentration range from 50 to
250 ng mL
-1 with a correlation coeﬃ-
cient higher than 0.995 in all cases. The
calibration parameters, limit of detection
(LOD), limit of quantiﬁcation (LOQ)
and linearity of the studied analytes were
determined according to International
Conference on Harmonization (ICH)
guidelines [39] (Table 4). The slope of
the standard addition calibration curve
was the parameter used to estimate the
sensitivity of the method. The instru-
ment precision was determined by a re-
peated injection of a worked up urine
sample at an analyte concentration of
100 ng mL
-1 (n = 5). The method pre-
cision was evaluated by extracting the
analytes from ﬁve aliquots of the same
urine (fortiﬁed with 100 ng mL
-1 ana-
lyte). All results are given in Table 4.
Phase II Metabolism:
Comparison with PABA
The in vitro phase II metabolism of EDP
was studied by incubating microsomes
and cytosolic solutions with diﬀerent
cofactors and subsequent LC-MS anal-
ysis. The targeted phase II metabolisa-
tions were the acetylation and the
glucuronidation through the reactions
with Acetyl Coenzyme A (AcCoA) and
UDP-GA, respectively. In these cases,
the phase I metabolism is a necessary
prerequisite for the subsequent conjuga-
tion.
The ﬁrst reaction was activated by
adding ATP to the cytosolic mixture.
Taking into account that the amino
group of DMP is dimethylated, acetyla-
tion is only possible for MMP via the
reaction of the monomethylated amino
group with AcCOA. However, no cor-
responding metabolite was found. As it
was stated before, a comparison of the
biotransformation for both EDP and
PABA may be helpful to understand the
metabolism of the studied UV ﬁlter.
Therefore, PABA incubations were car-
ried out under the same conditions as
stated for EDP. The expected acetylated
PABA metabolite was detected and the
identiﬁcation was conﬁrmed by com-
paring MS-MS measurements with ref-
erence material. This shows that the
proper reaction conditions were chosen.
Figure 5 shows the MS–MS spectra of
acetylated PABA. In fact, PABA is
considered a typical substrate of cyto-
solic arylamine N-acetyltransferase
(NAT) [40].
In order to asses the glucuronidation
of EDP and PABA, four series of
experiments were carried out using both
rat and human liver microsomes. How-
ever, no glucuronide conjugates could be
detected in any of the cases.
The results obtained from the in
vitro phase II metabolism study of
EDP indicate that EDP is not involved
in either acetylation or glucuronidation
processes. According to these results,
the biotransformation of EDP seems to
be limited to phase I metabolism.
However, other types of conjugation
reactions (i.e. sulfonation, etc.) should
be studied in order to get a more
general idea about the EDP phase II
biotransformation. The comparison of
EDP with PABA showed that the
phase II metabolism of EDP does not
involve acetylation, whereas PABA
served as a positive control for the
employed reaction conditions showing
the well known acetyl- adduct of
PABA [40]. This can possibly be ex-
plained through the steric impedance
observed by the methylated amino
group. On the other hand, none of the
substances showed any detectable
glucuronidation.
Conclusion
As EDP is a sunscreen ingredient show-
ing endocrine activity [11], there is a need
in understanding its metabolism and
distribution in the human body. There-
fore, the in vitro biotransformation of
EDP was studied. Two phase I metabo-
lites of EDP, namely MMP and DMP,
could be identiﬁed by both GC-MS and
LC-MS analysis.
Phase II metabolism was also inves-
tigated by means of glucuronidation
with UDP-GA and acetylation with
AcCOA. In both cases, PABA was used
as a well described reference compound.
While the acetylation product of PABA
was found, no acetylated or glucuroni-
dated conjugates were detected in the
case of EDP. This leads to the conclu-
sion that EDP basically undergoes phase
I metabolism.
Table 3. Determination of MMP, DMP and EDP in spiked real urine samples
Sample MMP DMP EDP
l
a (ng mL
-1)C
b ± s (ng mL
-1) tcal
c l
a (ng mL
-1)C
b ± s (ng mL
-1) tcal
c l
a (ng mL
-1)C
b ± s (ng mL
-1) tcal
c
13 4 2 6 ± 7 2.30 32 36 ± 7 1.59 29 34 ± 5 1.90
29 0 8 8 ± 6 0.59 84 81 ± 10 0.69 78 83 ± 6 1.88
3 112 104 ± 8 2.24 105 108 ± 9 0.50 98 107 ± 8 2.74
4 140 132 ± 10 1.60 132 123 ± 9 2.22 122 128 ± 5 2.41
5 169 167 ± 6 0.49 158 153 ± 10 1.27 146 148 ± 6 0.62
a Added concentration
b Found concentration
c ttab(0.05, N - 2 = 3) = 3.18
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based on SPE combined with LC-MS for
the determination of EDP and its phase I
metabolites at low ng mL
-1 levels in
human urine samples was developed.
The described SPE method showed a
very high eﬃciency and versatility
regarding the extraction of the lipohilic
EDP and its hydrophilic metabolites
from urine. The standard addition cali-
bration was used in order to correct
matrix eﬀects present in the urine sam-
ples. The analytical method was fully
validated, giving statistically accurate
results.
The high sensitivity of the developed
method may enable its application to in
vivo studies concerning the urinary
excretion of EDP and its phase I
metabolites. This will allow the estima-
tion of the total absorption, accumula-
tion and excretion of EDP due to the
ability to determine not only the free
EDP form urine samples, but also its
metabolites. In general, this should allow
gaining further insights into the toxicol-
ogy of this widely applied substance.
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